Cardiff Oncology
CRDF
73 hedge funds and large institutions have $223M invested in Cardiff Oncology in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 28 closing their positions.
146% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 13
10.4% less ownership
Funds ownership: 75.39% → 64.99% (-10%)
11% less funds holding
Funds holding: 82 → 73 (-9)
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $479M → $223M (-$256M)
56% less call options, than puts
Call options by funds: $3.69M | Put options by funds: $8.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$21.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.2M |
| 3 |
Janus Henderson Group
London,
|
+$9.71M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$9.54M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$59.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$30.8M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$13.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.53M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.49M |
CRDF Hedge Fund Activity: Q1 2021 in Review
73 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2021, worth a combined $223M — down 53% from $479M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CRDF and 19 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 32 added.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $21.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $59.2M sold.
- 73 institutional investors held Cardiff Oncology (CRDF) as of Q1 2021, down from 82 in Q4 2020.
- Funds reported $223M of Cardiff Oncology stock for Q1 2021, down 53% quarter-over-quarter.
- 19 funds opened new Cardiff Oncology positions in Q1 2021 and 28 closed out, a net change of -9 holders.
- The largest Cardiff Oncology buyer in Q1 2021 was Eventide Asset Management, an estimated $21.7M added.
- The largest Cardiff Oncology seller in Q1 2021 was RA Capital Management, an estimated $59.2M sold.
Based on aggregated 13F filings for Q1 2021.